SCHEMBL680240

SCHEMBL680240

CC(C)Cn1c(=O)n(C)c(=O)c2c(Sc3ccccc3)n(CC3CCN(C(C)C)CC3)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 6/20 0.44
PDE1A P54750 5/20 0.44
PDE1C Q14123 5/20 0.44
LMNA P02545 1/20 0.37
STAT3 P40763 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE2A O00408 3/20 0.36
PDE5A O76074 3/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CFTR P13569 1/20 0.34
TSHR P16473 1/20 0.34
PDE4A P27815 1/20 0.34
MAPK1 P28482 1/20 0.34
ADORA1 P30542 1/20 0.34
SCN1A P35498 1/20 0.34
PDE6C P51160 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2612353 0.77 PDE1B (0.53) PDE1BPDE1APDE1CLMNAPDE2A
SCHEMBL678876 0.76 PDE1A (0.48) PDE1BPDE1APDE1CLMNASTAT3
SCHEMBL15943410 0.75 PDE1B (0.47) PDE1BPDE1APDE1CLMNASTAT3
SCHEMBL679944 0.74 PDE1B (0.47) PDE1BPDE1APDE1CLMNASTAT3
SCHEMBL679958 0.74 PDE1B (0.46) PDE1BPDE1APDE1CLMNASTAT3
SCHEMBL9608322 0.69 PDE1B (0.44) PDE1BPDE1APDE1CPDE2ACYP3A4
SCHEMBL3083046 0.68 PDE1B (0.53) PDE1BPDE1APDE1CPDE2AADORA1
SCHEMBL678927 0.67 PDE1B (0.44) PDE1BPDE1APDE1CHRH3
SCHEMBL15943450 0.67 PDE1B (0.45) PDE1BPDE1APDE1CHRH3
SCHEMBL680003 0.66 USP1 (0.48) PDE1BPDE1APDE1CLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
EP-2367430-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2014-08-13 EP disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 PDE1B 4882/4885PDE1A 4885/4885PDE1C 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.